US Broker Ratings

Sanara MedTech Inc. (SMTI) Investor Outlook: Exploring a 74% Upside Potential in the Healthcare Sector

Sanara MedTech Inc. (NASDAQ: SMTI) is a compelling player in the healthcare sector, specializing in innovative medical instruments and supplies. With its headquarters in Fort Worth, Texas, the company is..

Grab Holdings Limited (GRAB) Stock Analysis: Unveiling a 26% Potential Upside for Investors

Grab Holdings Limited (NASDAQ: GRAB) is capturing investor attention with its significant growth trajectory and a noticeable potential upside of 26.41%. As a prominent player in the Technology sector, focusing..

Aura Biosciences, Inc. (AURA) Stock Analysis: Uncovering a 227% Potential Upside in Biotechnology

Aura Biosciences, Inc. (NASDAQ: AURA) stands out in the biotechnology sector, primarily due to its innovative approach towards treating solid tumors. As a clinical-stage company, Aura is on the cusp..

Materialise NV (MTLS) Stock Analysis: Exploring a 72% Upside Potential in the 3D Printing Sector

Materialise NV (NASDAQ: MTLS), a prominent player in the 3D printing industry, is capturing investor attention with its promising upside potential of 72%. The Belgian-based company, with a market capitalization..

Quantum-Si Incorporated (QSI) Investor Outlook: Exploring a 40% Upside Potential

Quantum-Si Incorporated (QSI), a healthcare sector innovator in the medical devices industry, is making waves with its cutting-edge single-molecule detection platform designed to revolutionize Next Generation Protein Sequencing (NGPS). With..

Alumis Inc. (ALMS) Stock Analysis: Exploring a Potential 617% Upside in the Biotech Sector

Alumis Inc. (NASDAQ: ALMS), a clinical-stage biopharmaceutical company, is creating waves in the biotechnology industry with its promising pipeline focused on autoimmune disorders. Despite its current price of $2.93, the..

aTyr Pharma, Inc. (ATYR) Stock Analysis: Exploring a Potential 278.67% Upside Opportunity

aTyr Pharma, Inc. (NASDAQ: ATYR) is making waves in the biotechnology sector with its groundbreaking approach to treating fibrosis and inflammation. Based in San Diego, California, this clinical-stage biotech company..

Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a 391% Potential Upside in the Biotech Arena

Compass Therapeutics, Inc. (NASDAQ: CMPX), a clinical-stage biopharmaceutical company, has captured the attention of investors with its oncology-focused pipeline and a remarkable potential upside of nearly 391.53%. As the company..

iTeos Therapeutics, Inc. (ITOS) Stock Analysis: Exploring the 9.56% Potential Upside in the Biotech Innovator

For investors keeping a close watch on the healthcare sector, iTeos Therapeutics, Inc. (NASDAQ: ITOS) presents a intriguing opportunity within the biotechnology industry. With a market capitalization of $384.27 million,..

Gossamer Bio, Inc. (GOSS) Investor Outlook: Unpacking a Potential 459% Upside

Gossamer Bio, Inc. (NASDAQ: GOSS), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its ambitious focus on developing treatments for pulmonary arterial hypertension (PAH). This San..

Neuronetics, Inc. (STIM) Stock Analysis: Aiming for a 99.8% Upside in the Medical Devices Sector

Neuronetics, Inc. (NASDAQ: STIM), based in Malvern, Pennsylvania, has carved a niche in the healthcare sector with its innovative NeuroStar Advanced Therapy System. This medical device uses transcranial magnetic stimulation..

Candel Therapeutics, Inc. (CADL) Stock Analysis: Exploring a Potential 346.74% Upside in the Biotech Sector

Candel Therapeutics, Inc. (NASDAQ: CADL) is making waves in the biotechnology sector with its innovative approach to cancer treatment through immunotherapy. As the company continues to advance its clinical-stage biopharmaceutical..

Neurogene Inc. (NGNE) Stock Analysis: Unveiling a 159.68% Potential Upside in the Biotech Sector

Neurogene Inc. (NASDAQ: NGNE) is capturing the attention of investors with a compelling potential upside of 159.68%. As a clinical-stage biotechnology company, Neurogene is at the forefront of developing genetic..

CytomX Therapeutics, Inc. (CTMX) Stock Analysis: Unveiling a 148.87% Potential Upside in Biotech

In the dynamic world of biotechnology, CytomX Therapeutics, Inc. (NASDAQ: CTMX) emerges as a noteworthy player with its innovative approach to cancer treatment. Operating at the forefront of biopharmaceutical developments,..

Arcturus Therapeutics Holdings (ARCT) Investor Outlook: Exploring a Potential 381% Upside in the Biotech Sector

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stands out in the biotechnology industry with its innovative approach to developing vaccines and therapeutics for infectious diseases and rare liver and respiratory conditions...

Pacific Biosciences of California (PACB) Stock Analysis: Exploring a 68% Upside Potential

Pacific Biosciences of California, Inc. (NASDAQ: PACB) stands at a significant crossroads in the healthcare sector, offering investors a unique opportunity to engage with a company that specializes in advanced..

Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Navigating a Promising Biotech Frontier with Potential Upside

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) stands at a compelling juncture within the biotech sector, showcasing potential opportunities amidst its ongoing clinical developments. With a market cap of approximately $386.49 million,..

XOMA Royalty Corporation (XOMA) Stock Analysis: Unlocking a Potential 135% Upside in the Biotech Sector

For investors with a keen interest in the biotechnology sector, XOMA Royalty Corporation (XOMA) presents an intriguing opportunity, bolstered by a remarkable potential upside of 135.58%. This California-based company operates..

Nano-X Imaging Ltd (NNOX) Stock Analysis: Exploring the 66.67% Upside Potential

Nano-X Imaging Ltd (NASDAQ: NNOX) is an intriguing player in the healthcare sector, specializing in revolutionary medical devices. Headquartered in Petah Tikva, Israel, the company has positioned itself as an..

Abeona Therapeutics Inc. (ABEO) Stock Analysis: A Biotech Gem with a 233% Upside Potential

Abeona Therapeutics Inc. (NASDAQ: ABEO) is making waves in the biotechnology sector with its innovative approach to gene and cell therapies aimed at treating life-threatening diseases. As a clinical-stage biopharmaceutical..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds